NorthWest Biotherapeutics Inc (NWBO)

[TZOR]

The problem with continue at this time is that it will allow for obfuscation from shorts who would argue that continue means that the results are not good enough for acceptance, FDA will have no problem with continuance because of lack of safety issues, and management has an interest in keeping the trial going as long as possible to continue to dilute.

We need something better than continuation to break the price upward.

I noticed a decent recommendation earlier today on YMB (seriously)

--- An acceptable response to the Phase V allegations.
--- A credible investigation report.
--- Resignation of Linda and the Board if there are any serious issues exposed, or an explanation of the poor management that allowed spurious allegations to so negatively impact the company.
--- A public statement from Woodford that he is satisfied with the investigation and the company's response and he is considering a new investment. I think a signal from Woodford will be critical to NWBO's hopes for future funding.

- New financing to carry us through completion of the current trials, at a fair cost to shareholders. Oh, good luck with out the above criteria satisfied)

- Clarification on the status of current trials and a promise of greater clarity going forward.

That and/or very detailed explanation as to what caused the temporary hold, what was submitted, and what was the resolution/outcome of the submission.

I have been here for years, and only until recently have I actually become critical (angry) of (with) management. Then again I am coming from the point of view of less than full information.

It makes me think that for the whole industry, there must be better ways of going through FDA trials. Meaning from an administrative point of view, there appears to be so many inefficiencies in the whole process for anyone who deals with the FDA clinical trials, or invests with companies working with the FDA.

I have been paying attention to competitors and other companies that have encountered similar temporary halts and it seems that the admin side of the FDA is not as efficient as it could/should be.